» Articles » PMID: 39402409

Resistant Hypertension: A Brief Review of Pathophysiology

Overview
Publisher Springer
Specialty General Medicine
Date 2024 Oct 14
PMID 39402409
Authors
Affiliations
Soon will be listed here.
Abstract

A 52-year-old male comes to the internal medicine clinic for a follow-up for the management of hypertension. He was initially diagnosed with hypertension 5 years ago. His other past medical history includes obesity and hyperlipidemia. His current medications currently include losartan 100 mg daily, hydrochlorothiazide 25 mg, and amlodipine 10 mg. His physical exam is significant for an elevated in-office blood pressure of 160/105 mmHg, BMI 38, and neck circumference > 40 cm. He also reports snoring at night and having significant daytime sleepiness despite getting over 8 hours of sleep each night. This patient meets the most recent diagnostic criteria per the American Heart Association for resistant hypertension. Resistant hypertension is an increasingly prevalent phenotype encountered in both primary care and subspecialty clinics. Multiple comorbidities, including obesity, sleep apnea, chronic kidney disease, heart failure, and diabetes mellitus, are associated with resistant hypertension. Our understanding of the potential etiologies for this condition continues to evolve rapidly. We used a narrative review to explore four research areas in the pathophysiology of resistant hypertension (the sympathetic nervous system, aldosterone excess, endothelial dysfunction, and inflammation) and explore the novel therapies currently in development.

References
1.
Ardhanari S, Kannuswamy R, Chaudhary K, Lockette W, Whaley-Connell A . Mineralocorticoid and apparent mineralocorticoid syndromes of secondary hypertension. Adv Chronic Kidney Dis. 2015; 22(3):185-95. DOI: 10.1053/j.ackd.2015.03.002. View

2.
Biffi A, Quarti-Trevano F, Bonzani M, Seravalle G, Corrao G, Mancia G . Neuroadrenergic activation in obstructive sleep apnoea syndrome: a new selected meta-analysis - revisited. J Hypertens. 2021; 40(1):15-23. PMC: 10871617. DOI: 10.1097/HJH.0000000000003045. View

3.
Puszkarska A, Niklas A, Gluszek J, Lipski D, Niklas K . The concentration of tumor necrosis factor in the blood serum and in the urine and selected early organ damages in patients with primary systemic arterial hypertension. Medicine (Baltimore). 2019; 98(22):e15773. PMC: 6709115. DOI: 10.1097/MD.0000000000015773. View

4.
Gan L, Ye D, Feng Y, Pan H, Lu X, Wan J . Immune cells and hypertension. Immunol Res. 2023; 72(1):1-13. DOI: 10.1007/s12026-023-09414-z. View

5.
Norlander A, Saleh M, Kamat N, Ko B, Gnecco J, Zhu L . Interleukin-17A Regulates Renal Sodium Transporters and Renal Injury in Angiotensin II-Induced Hypertension. Hypertension. 2016; 68(1):167-74. PMC: 4900947. DOI: 10.1161/HYPERTENSIONAHA.116.07493. View